Skip to content
Conditions & Health

Insulin resistance

A condition where cells respond poorly to insulin, requiring the pancreas to produce more insulin to maintain normal blood sugar. A precursor to type 2 diabetes. GLP-1 agonists improve insulin sensitivity.

Frequently Asked Questions

What is Insulin resistance?
A condition where cells respond poorly to insulin, requiring the pancreas to produce more insulin to maintain normal blood sugar. A precursor to type 2 diabetes. GLP-1 agonists improve insulin sensitivity.
Why is Insulin resistance important in peptide research?
Understanding insulin resistance is important because it represents a health condition where peptide interventions are being actively researched. Knowledge of the underlying pathology helps inform peptide selection and protocol design.

Related Terms

Type 2 diabetes

A metabolic disease characterized by chronically elevated blood sugar due to insulin resistance and inadequate insulin secretion. GLP-1 agonists (semaglutide, tirzepatide, liraglutide) are first-line treatments.

Metabolic syndrome

A cluster of conditions including central obesity, elevated blood sugar, high blood pressure, and abnormal cholesterol that together increase the risk of heart disease, stroke, and type 2 diabetes.

GLP-1

Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The therapeutic target of blockbuster drugs semaglutide, tirzepatide, and liraglutide.

Related Peptide Profiles

Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.

Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.

← Back to full glossary